1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Tyrosine	_	_	NNP	_	_	_	_	_
2	kinase	_	_	NN	_	_	_	_	_
3	inhibitors	_	_	NNS	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	TKIs	_	_	NNPS	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	widely	_	_	RB	_	_	_	_	_
9	used	_	_	VBN	_	_	_	_	_
10	drugs	_	_	NNS	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	targeted	_	_	VBN	_	_	_	_	_
14	strategy	_	_	NN	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	cancer	_	_	NN	_	_	_	_	_
17	treatment	_	_	NN	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	aim	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	prolonging	_	_	VBG	_	_	_	_	_
23	progression-free	_	_	JJ	_	_	_	_	_
24	survival	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Deregulated	_	_	JJ	_	_	_	_	_
2	tyrosine	_	_	NN	_	_	_	_	_
3	kinase	_	_	NN	_	_	_	_	_
4	activity	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	BCR-ABL	_	_	NNP	_	_	_	_	_
8	oncoprotein	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	biochemical	_	_	JJ	_	_	_	_	_
12	hallmark	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	Philadelphia	_	_	NNP	_	_	_	_	_
15	chromosome-positive	_	_	JJ	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	Ph+	_	_	NN	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	hematological	_	_	JJ	_	_	_	_	_
20	malignancies	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Currently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	several	_	_	JJ	_	_	_	_	_
4	generations	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	BCR-ABL	_	_	NNP	_	_	_	_	_
7	TKIs	_	_	NNPS	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	clinical	_	_	JJ	_	_	_	_	_
11	use	_	_	NN	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	treatment	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	these	_	_	DT	_	_	_	_	_
16	malignancies	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	second-generation	_	_	JJ	_	_	_	_	_
5	TKIs	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	nilotinib	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	dasatinib	_	_	NN	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	first-line	_	_	JJ	_	_	_	_	_
12	treatment	_	_	NN	_	_	_	_	_
13	resulted	_	_	VBD	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	rapid	_	_	JJ	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	deep	_	_	JJ	_	_	_	_	_
18	reduction	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	BCR/ABL1	_	_	NNP	_	_	_	_	_
21	allele	_	_	NN	_	_	_	_	_
22	transcripts	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	this	_	_	DT	_	_	_	_	_
26	provided	_	_	VBD	_	_	_	_	_
27	a	_	_	DT	_	_	_	_	_
28	possibility	_	_	NN	_	_	_	_	_
29	for	_	_	IN	_	_	_	_	_
30	long-term	_	_	JJ	_	_	_	_	_
31	survival	_	_	NN	_	_	_	_	_
32	in	_	_	IN	_	_	_	_	_
33	CML	_	_	NNP	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	CML	_	_	NNP	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	several	_	_	JJ	_	_	_	_	_
7	other	_	_	JJ	_	_	_	_	_
8	patient	_	_	NN	_	_	_	_	_
9	populations	_	_	NNS	_	_	_	_	_
10	were	_	_	VBD	_	_	_	_	_
11	identified	_	_	VBN	_	_	_	_	_
12	that	_	_	WDT	_	_	_	_	_
13	undoubtedly	_	_	RB	_	_	_	_	_
14	benefited	_	_	VBN	_	_	_	_	_
15	from	_	_	IN	_	_	_	_	_
16	TKI	_	_	NNP	_	_	_	_	_
17	treatment	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Patients	_	_	NNS	_	_	_	_	_
2	with	_	_	IN	_	_	_	_	_
3	Ph+	_	_	NN	_	_	_	_	_
4	adult	_	_	JJ	_	_	_	_	_
5	acute	_	_	JJ	_	_	_	_	_
6	lymphoblastic	_	_	JJ	_	_	_	_	_
7	leukemia	_	_	NN	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	ALL	_	_	DT	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	may	_	_	MD	_	_	_	_	_
12	also	_	_	RB	_	_	_	_	_
13	benefit	_	_	VB	_	_	_	_	_
14	from	_	_	IN	_	_	_	_	_
15	an	_	_	DT	_	_	_	_	_
16	alternate	_	_	JJ	_	_	_	_	_
17	TKI	_	_	NN	_	_	_	_	_
18	therapy	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	treatment	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	pediatric	_	_	JJ	_	_	_	_	_
6	patients	_	_	NNS	_	_	_	_	_
7	with	_	_	IN	_	_	_	_	_
8	Ph+	_	_	NNP	_	_	_	_	_
9	ALL	_	_	PDT	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	addition	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	TKIs	_	_	NNS	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	conventional	_	_	JJ	_	_	_	_	_
16	chemotherapy	_	_	NN	_	_	_	_	_
17	has	_	_	VBZ	_	_	_	_	_
18	improved	_	_	VBN	_	_	_	_	_
19	outcomes	_	_	NNS	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	patients	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	long	_	_	RB	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	known	_	_	VBN	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	second-generation	_	_	JJ	_	_	_	_	_
8	TKIs	_	_	NNS	_	_	_	_	_
9	may	_	_	MD	_	_	_	_	_
10	have	_	_	VB	_	_	_	_	_
11	side	_	_	NN	_	_	_	_	_
12	effects	_	_	NNS	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	nilotinib	_	_	NN	_	_	_	_	_
15	can	_	_	MD	_	_	_	_	_
16	potentiate	_	_	VB	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	prothrombotic	_	_	JJ	_	_	_	_	_
19	state	_	_	NN	_	_	_	_	_
20	while	_	_	IN	_	_	_	_	_
21	dasatinib	_	_	NN	_	_	_	_	_
22	is	_	_	VBZ	_	_	_	_	_
23	known	_	_	VBN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	cause	_	_	VB	_	_	_	_	_
26	platelet	_	_	NN	_	_	_	_	_
27	dysfunction	_	_	NN	_	_	_	_	_
28	e.g.	_	_	IN	_	_	_	_	_
29	impaired	_	_	VBN	_	_	_	_	_
30	collagen-induced	_	_	JJ	_	_	_	_	_
31	platelet	_	_	NN	_	_	_	_	_
32	adhesion	_	_	NN	_	_	_	_	_
33	and	_	_	CC	_	_	_	_	_
34	aggregation	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	both	_	_	DT	_	_	_	_	_
3	drugs	_	_	NNS	_	_	_	_	_
4	bind	_	_	VBP	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	ATP	_	_	NNP	_	_	_	_	_
8	binding	_	_	VBG	_	_	_	_	_
9	site	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	kinase	_	_	NN	_	_	_	_	_
13	domain	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	BCR/ABL	_	_	NNP	_	_	_	_	_
17	protein	_	_	NN	_	_	_	_	_
18	they	_	_	PRP	_	_	_	_	_
19	have	_	_	VBP	_	_	_	_	_
20	different	_	_	JJ	_	_	_	_	_
21	off	_	_	JJ	_	_	_	_	_
22	target	_	_	NN	_	_	_	_	_
23	inhibitory	_	_	JJ	_	_	_	_	_
24	effect	_	_	NN	_	_	_	_	_
25	on	_	_	IN	_	_	_	_	_
26	several	_	_	JJ	_	_	_	_	_
27	other	_	_	JJ	_	_	_	_	_
28	tyrosine	_	_	NN	_	_	_	_	_
29	kinases	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Dasatinib	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	potent	_	_	JJ	_	_	_	_	_
5	multikinase	_	_	NN	_	_	_	_	_
6	inhibitor	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	including	_	_	VBG	_	_	_	_	_
9	c-KIT	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	EPHA2	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	platelet-derived	_	_	JJ	_	_	_	_	_
14	growth	_	_	NN	_	_	_	_	_
15	factor	_	_	NN	_	_	_	_	_
16	receptor-Î²	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	SFKs	_	_	NNP	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Nilotinib	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	also	_	_	RB	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	second	_	_	JJ	_	_	_	_	_
6	generation	_	_	NN	_	_	_	_	_
7	TKI	_	_	NN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	broad	_	_	JJ	_	_	_	_	_
11	inhibitory	_	_	JJ	_	_	_	_	_
12	spectrum	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	various	_	_	JJ	_	_	_	_	_
15	tyrosine	_	_	NN	_	_	_	_	_
16	kinases	_	_	NNS	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	PDGFR	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	c-KIT	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	ARG	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	EPHB4	_	_	NNP	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	but	_	_	CC	_	_	_	_	_
28	it	_	_	PRP	_	_	_	_	_
29	does	_	_	VBZ	_	_	_	_	_
30	not	_	_	RB	_	_	_	_	_
31	inhibit	_	_	VB	_	_	_	_	_
32	SFKs	_	_	NNP	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Previous	_	_	JJ	_	_	_	_	_
2	in	_	_	IN	_	_	_	_	_
3	vitro	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	ex	_	_	NN	_	_	_	_	_
6	vivo	_	_	NN	_	_	_	_	_
7	studies	_	_	NNS	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	dasatinib	_	_	NN	_	_	_	_	_
10	have	_	_	VBP	_	_	_	_	_
11	demonstrated	_	_	VBN	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	faulty	_	_	JJ	_	_	_	_	_
14	platelet	_	_	NN	_	_	_	_	_
15	aggregation	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	On	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	contrary	_	_	NN	_	_	_	_	_
4	nilotinib	_	_	NN	_	_	_	_	_
5	has	_	_	VBZ	_	_	_	_	_
6	no	_	_	DT	_	_	_	_	_
7	effect	_	_	NN	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	platelet	_	_	NN	_	_	_	_	_
10	aggregation	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	at	_	_	IN	_	_	_	_	_
13	all	_	_	DT	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	used	_	_	VBD	_	_	_	_	_
5	nilotinib	_	_	NN	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	negative	_	_	JJ	_	_	_	_	_
9	control	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	our	_	_	PRP$	_	_	_	_	_
12	experiments	_	_	NNS	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Sarcoma	_	_	NNP	_	_	_	_	_
2	family	_	_	NN	_	_	_	_	_
3	kinases	_	_	NNS	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	SFKs	_	_	NNP	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	critical	_	_	JJ	_	_	_	_	_
9	regulators	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	platelet	_	_	NN	_	_	_	_	_
12	signaling	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	activation	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	kinases	_	_	NNS	_	_	_	_	_
3	play	_	_	VBP	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	central	_	_	JJ	_	_	_	_	_
6	role	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	mediating	_	_	VBG	_	_	_	_	_
9	rapid	_	_	JJ	_	_	_	_	_
10	response	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	platelets	_	_	NNS	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	vascular	_	_	JJ	_	_	_	_	_
15	injury	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	transmit	_	_	VBP	_	_	_	_	_
3	activation	_	_	NN	_	_	_	_	_
4	signals	_	_	NNS	_	_	_	_	_
5	from	_	_	IN	_	_	_	_	_
6	several	_	_	JJ	_	_	_	_	_
7	various	_	_	JJ	_	_	_	_	_
8	platelet	_	_	NN	_	_	_	_	_
9	receptors	_	_	NNS	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	numerous	_	_	JJ	_	_	_	_	_
4	members	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	this	_	_	DT	_	_	_	_	_
7	group	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	among	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	SFKs	_	_	NNP	_	_	_	_	_
12	Lyn	_	_	NNP	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	Fyn	_	_	NNP	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	Src	_	_	NNP	_	_	_	_	_
18	have	_	_	VBP	_	_	_	_	_
19	been	_	_	VBN	_	_	_	_	_
20	implicated	_	_	VBN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	activation	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	GPVI	_	_	NNP	_	_	_	_	_
26	receptor	_	_	NN	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	integrin	_	_	NN	_	_	_	_	_
30	receptor	_	_	NN	_	_	_	_	_
31	signaling	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	are	_	_	VBP	_	_	_	_	_
34	frequently	_	_	RB	_	_	_	_	_
35	studied	_	_	VBN	_	_	_	_	_
36	proteins	_	_	NNS	_	_	_	_	_
37	as	_	_	IN	_	_	_	_	_
38	they	_	_	PRP	_	_	_	_	_
39	are	_	_	VBP	_	_	_	_	_
40	present	_	_	JJ	_	_	_	_	_
41	in	_	_	IN	_	_	_	_	_
42	both	_	_	CC	_	_	_	_	_
43	human	_	_	JJ	_	_	_	_	_
44	and	_	_	CC	_	_	_	_	_
45	mouse	_	_	NN	_	_	_	_	_
46	platelets	_	_	NNS	_	_	_	_	_
47	.	_	_	.	_	_	_	_	_


1	TKIs	_	_	PRP	_	_	_	_	_
2	have	_	_	VBP	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	different	_	_	JJ	_	_	_	_	_
5	off-target	_	_	JJ	_	_	_	_	_
6	multikinase	_	_	NN	_	_	_	_	_
7	inhibitory	_	_	JJ	_	_	_	_	_
8	effect	_	_	NN	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	Comprehensive	_	_	JJ	_	_	_	_	_
2	drug-protein	_	_	NN	_	_	_	_	_
3	interaction	_	_	NN	_	_	_	_	_
4	profiles	_	_	NNS	_	_	_	_	_
5	were	_	_	VBD	_	_	_	_	_
6	described	_	_	VBN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	predict	_	_	VB	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	potential	_	_	JJ	_	_	_	_	_
11	side	_	_	NN	_	_	_	_	_
12	effects	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	BCR-ABL	_	_	NNP	_	_	_	_	_
15	TKIs	_	_	NNPS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	was	_	_	VBD	_	_	_	_	_
3	found	_	_	VBN	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	most	_	_	RBS	_	_	_	_	_
7	prominent	_	_	JJ	_	_	_	_	_
8	dasatinib-targeted	_	_	JJ	_	_	_	_	_
9	SFKs	_	_	NNS	_	_	_	_	_
10	are	_	_	VBP	_	_	_	_	_
11	Lyn	_	_	NNP	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	Fyn	_	_	NNP	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	Src	_	_	NNP	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	kinases	_	_	NNS	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	their	_	_	PRP$	_	_	_	_	_
21	negative	_	_	JJ	_	_	_	_	_
22	regulator	_	_	NN	_	_	_	_	_
23	C-terminal	_	_	NNP	_	_	_	_	_
24	Src	_	_	NNP	_	_	_	_	_
25	kinase	_	_	NNP	_	_	_	_	_
26	(	_	_	-LRB-	_	_	_	_	_
27	Csk	_	_	NNP	_	_	_	_	_
28	)	_	_	-RRB-	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	but	_	_	CC	_	_	_	_	_
31	nilotinib	_	_	NN	_	_	_	_	_
32	does	_	_	VBZ	_	_	_	_	_
33	not	_	_	RB	_	_	_	_	_
34	bind	_	_	VB	_	_	_	_	_
35	to	_	_	TO	_	_	_	_	_
36	these	_	_	DT	_	_	_	_	_
37	kinases	_	_	NNS	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	During	_	_	IN	_	_	_	_	_
2	vascular	_	_	JJ	_	_	_	_	_
3	injury	_	_	NN	_	_	_	_	_
4	it	_	_	PRP	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	primarily	_	_	RB	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	subendothelial	_	_	JJ	_	_	_	_	_
9	collagen	_	_	NN	_	_	_	_	_
10	that	_	_	WDT	_	_	_	_	_
11	activates	_	_	VBZ	_	_	_	_	_
12	platelets	_	_	NNS	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	result	_	_	VB	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	subsequent	_	_	JJ	_	_	_	_	_
17	platelet	_	_	NN	_	_	_	_	_
18	aggregation	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	population	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	collagen-adhered	_	_	JJ	_	_	_	_	_
6	platelets	_	_	NNS	_	_	_	_	_
7	responds	_	_	VBZ	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	surface	_	_	NN	_	_	_	_	_
10	exposure	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	procoagulant	_	_	JJ	_	_	_	_	_
14	phosphatidylserine	_	_	NN	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	PS	_	_	NN	_	_	_	_	_
17	)	_	_	-RRB-	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	surface	_	_	NN	_	_	_	_	_
3	expressed	_	_	VBD	_	_	_	_	_
4	PS	_	_	NN	_	_	_	_	_
5	facilitates	_	_	VBZ	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	binding	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	coagulation	_	_	NN	_	_	_	_	_
10	factors	_	_	NNS	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	this	_	_	DT	_	_	_	_	_
14	promotes	_	_	VBZ	_	_	_	_	_
15	thrombin	_	_	NN	_	_	_	_	_
16	generation	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	platelets	_	_	NNS	_	_	_	_	_
5	participate	_	_	VBP	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	fibrin	_	_	NN	_	_	_	_	_
8	formation	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	regulate	_	_	VB	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	process	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	clot	_	_	NN	_	_	_	_	_
15	retraction	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	intended	_	_	VBD	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	investigate	_	_	VB	_	_	_	_	_
5	whether	_	_	IN	_	_	_	_	_
6	dasatinib	_	_	NN	_	_	_	_	_
7	also	_	_	RB	_	_	_	_	_
8	affects	_	_	VBZ	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	platelet	_	_	NN	_	_	_	_	_
11	procoagulant	_	_	JJ	_	_	_	_	_
12	activity	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	thereby	_	_	RB	_	_	_	_	_
15	coagulation	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	reason	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	examined	_	_	VBD	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	vitro	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	ex	_	_	NN	_	_	_	_	_
12	vivo	_	_	NN	_	_	_	_	_
13	effects	_	_	NNS	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	dasatinib	_	_	NN	_	_	_	_	_
16	on	_	_	IN	_	_	_	_	_
17	platelet	_	_	NN	_	_	_	_	_
18	procoagulant	_	_	NN	_	_	_	_	_
19	response	_	_	NN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	dasatinib	_	_	NN	_	_	_	_	_
22	treated	_	_	VBN	_	_	_	_	_
23	platelets	_	_	NNS	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	healthy	_	_	JJ	_	_	_	_	_
26	volunteers	_	_	NNS	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	samples	_	_	NNS	_	_	_	_	_
30	derived	_	_	VBN	_	_	_	_	_
31	from	_	_	IN	_	_	_	_	_
32	CML	_	_	NNP	_	_	_	_	_
33	patients	_	_	NNS	_	_	_	_	_
34	on	_	_	IN	_	_	_	_	_
35	dasatinib	_	_	NN	_	_	_	_	_
36	therapy	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	found	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	at	_	_	IN	_	_	_	_	_
5	therapeutic	_	_	JJ	_	_	_	_	_
6	concentration	_	_	NN	_	_	_	_	_
7	dasatainib	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	but	_	_	CC	_	_	_	_	_
10	not	_	_	RB	_	_	_	_	_
11	nilotinib	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	has	_	_	VBZ	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	strong	_	_	JJ	_	_	_	_	_
16	inhibitory	_	_	JJ	_	_	_	_	_
17	effect	_	_	NN	_	_	_	_	_
18	on	_	_	IN	_	_	_	_	_
19	platelet	_	_	NN	_	_	_	_	_
20	procoagulant	_	_	NN	_	_	_	_	_
21	activity	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	on	_	_	IN	_	_	_	_	_
24	clot	_	_	NN	_	_	_	_	_
25	retraction	_	_	NN	_	_	_	_	_
26	both	_	_	CC	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	non	_	_	NN	_	_	_	_	_
29	activated	_	_	VBN	_	_	_	_	_
30	as	_	_	RB	_	_	_	_	_
31	well	_	_	RB	_	_	_	_	_
32	as	_	_	IN	_	_	_	_	_
33	in	_	_	IN	_	_	_	_	_
34	convulxin	_	_	NN	_	_	_	_	_
35	activated	_	_	VBN	_	_	_	_	_
36	platelets	_	_	NNS	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_

